TM4SF4 and cancer: Collectively, these findings demonstrate that the 2B7 antibody, which showed effective antitumor efficacy in NSCLC xenograft models, inhibited TM4SF4-mediated cancer stemness and EMT and provided evidence of its therapeutic potential in extrapulmonary cancer types.